I think it will have enough cash (after tomorrow) for: the percutaneous trial (20 patients), to finish the current folfirinox study, to complete FDA application process for cholangio and to retry the TGA.
The GBA application isn't requiring cash and is meant to be cash flow positive if they get it (as opposed to the above which require company funding).
Of course they want commercial agreements and they have implemented quite a few. The more sales the less pressure on the company to raise capital. But they haven't given guidance on expected sales as yet. I'm not saying they don;t need sales, they obviously do. But the other things they are doing are very valuable
Ann: Two more PANCOSIL Trial treatments using OncoSil device, page-79
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.23 |
Change
0.210(20.6%) |
Mkt cap ! $17.49M | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.24 | $1.03 | $200.2K | 169.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3500 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 60000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |